Foti A G, Cooper J F, Herschman H, Malvaez R R
N Engl J Med. 1977 Dec 22;297(25):1357-61. doi: 10.1056/NEJM197712222972501.
We compared our radioimmunoassay with the standard enzyme assay for prostatic acid phosphatase in the diagnosis of prostatic cancer. Serum samples from 50 controls, 113 patients with prostatic cancer, 36 with benign prostatic hyperplasia, 83 with other cancers, 20 with gastrointestinal disorders and 28 with total prostatectomies were randomized and studied by radioimmunoassay and enzyme assay. When the upper limit was set at 8.0 ng per milliliter (mean + 4 S.D.) the radioimmunoassay diagnosed prostatic cancer in 33, 79, 71 and 92 per cent of the patients with Stage I, II, III and IV disease. In contrast, the enzyme assay detected elevations of enzyme in the serum of 12, 15, 29, and 60 per cent respectively. No false-positive results were detected by either assay in normal controls but the radioimmunoassay test was positive in two patients with benign prostatic hyperplasia, in one patient after total prostatectomy, in nine with other cancers and in one of the group with gastrointestinal disorders. In contrast to the enzyme assay, the radioimmunoassay distinguished over half the cases of intracapsular prostatic cancer.
我们将我们的放射免疫测定法与前列腺酸性磷酸酶的标准酶测定法进行了比较，以用于前列腺癌的诊断。对来自50名对照者、113名前列腺癌患者、36名良性前列腺增生患者、83名其他癌症患者、20名胃肠道疾病患者和28名接受全前列腺切除术患者的血清样本进行随机分组，并采用放射免疫测定法和酶测定法进行研究。当上限设定为每毫升8.0纳克（均值 + 4个标准差）时，放射免疫测定法诊断出I期、II期、III期和IV期疾病患者中前列腺癌的比例分别为33%、79%、71%和92%。相比之下，酶测定法分别检测出血清中酶升高的比例为12%、15%、29%和60%。两种测定法在正常对照者中均未检测到假阳性结果，但放射免疫测定法在两名良性前列腺增生患者、一名全前列腺切除术后患者、九名其他癌症患者和一名胃肠道疾病患者中呈阳性。与酶测定法不同，放射免疫测定法能区分出一半以上的包膜内前列腺癌病例。
